Chromatin Immunoprecipitation (ChIP)
Immunocytochemistry (ICC): 1:1,000
Immunohistochemistry (IHC): 1:100
Dot Blot: 1:1,000
Flow Cytometry
Immunoprecipitation (IP)
Reactive Species | Human |
---|---|
Target UniProt ID | NA |
Target Alternative Names | DNA-RNA Duplex |
Target Molecular Weight (kDa) | NA |
Sensitivity | Endogenous |
Host / lsotype | Mouse / IgG2a |
Class | Recombinant Antibody |
Clone | S9.6-L |
Expression System | CHO |
Immunogen | DNA-RNA heteropolymer duplex |
Purification | Protein G |
Conjugate | Unconjugated |
Form | Liquid |
Concentration | 0.5 mg/mL |
Storage Buffer | PBS, 0.05% BSA, 0.04% Proclin 300 |
Storage Condition | -20°C |
DNA-RNA hybrids are double-stranded nucleic acid structures consisting of one DNA strand and one complementary RNA strand. They form naturally during transcription when RNA is synthesized from a DNA template, resulting in transient RNA-DNA duplexes. These hybrids play significant roles in various cellular processes, including transcriptional regulation and genome stability. However, their persistence can lead to genomic instability, a hallmark of cancer and genetic diseases. Additionally, mutations in proteins responsible for resolving DNA-RNA hybrids, such as the RNA-DNA helicase senataxin (SETX), have been linked to neurological disorders like amyotrophic lateral sclerosis type 4 and ataxia oculomotor apraxia type 2. Understanding the dynamics of DNA-RNA hybrid formation and resolution is crucial for insights into gene expression regulation and the maintenance of genomic integrity.Chromatin Immunoprecipitation (ChIP) Analysis: Bhatia, V., et al. (2014). Nature. 511(7509):362-365; Skourti-Stathaki, K., et al. (2011). Mol. Cell. 42(6):794-805. Chromatin Immunoprecipitation-sequencing (ChIP-seq) Analysis: El Hage, A., et al. (2014). PLoS Genet. 10(10):e1004716. Immunocytochemistry Analysis: Bhatia, V., et al. (2014). Nature. 511(7509):362-365; Ginno, P.A., et al. (2012). Mol. Cell. 45(6):814-825. Immunoprecipitation Analysis: Ginno, P.A., et al. (2012). Mol. Cell. 45(6):814-825.